Abstract 1245P
Background
Specific requirements of the minimum number of harvested lymph nodes for accurate nodal staging in small intestinal tumors are sparse as there is a probability that false-negative lymph nodes remain. The aim of this study is to establish a histologic-type-specific nodal staging score (NSS) model for the specific requirements of lymph nodes in small intestinal tumors by taking potential false-negative lymph nodes into consideration.
Methods
Small intestinal tumors with complete follow-up and examined/positive lymph nodes data were retrieved using the Surveillance, Epidemiology, and End Results program. Using a beta-binomial model, the probability of lymph nodes with occult disease and the NSS model were established.
Results
A total of 7649 small intestinal tumors were retrieved, including 3789 carcinoid cases, 2467 adenocarcinoma cases, 718 neuroendocrine carcinoma cases, 502 sarcoma cases, and 173 others. To reach a 0.05 false-negative probability, the minimum number of lymph nodes was 10 in carcinoid tumors, 11 in adenocarcinoma, 12 in neuroendocrine carcinoma, 7 in sarcoma, and 16 in others. Distinct NSS curves were presented among each histologic type of small intestinal tumors. The NSS of neuroendocrine carcinoma indicated that a higher number of lymph nodes was required to enable the correct staging of lymph nodes compared to other types of small intestinal tumors. The prognostic values of NSS quartiles were validated.
Conclusions
The minimum required number of examined lymph nodes varied in each histologic type of small intestinal tumors. The NSS improved the adequacy of nodal staging for patients for clinical interpretation and decision making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1219P - Artificial intelligence-based breast cancer detection facilitates automated prognosis marker assessment using multiplex fluorescence immunohistochemistry
Presenter: Tim Mandelkow
Session: Poster session 14
1220P - Comprehensive diagnose of programmed death-ligand 1 from two-dimensional to three-dimensional in breast cancer with computer-aided artificial intelligence system
Presenter: Yi-Hsuan Lee
Session: Poster session 14
1221P - The functional domain of BRCA1/2 pathogenic variants (PVs) as potential biomarkers of second tumor and domain-related sensitivity to PARP-inhibitors
Presenter: Lorena Incorvaia
Session: Poster session 14
1222P - Detection of androgen-receptor splice variant 7 messenger RNA in circulating tumor cells of prostate cancer by in vitro assay
Presenter: Hoin Kang
Session: Poster session 14
1223P - Homologous recombination deficiency (HRD) testing on ovarian cancer ascites: A feasibility study
Presenter: Alberto Ranghiero
Session: Poster session 14
1224P - Detection of circulating tumor DNA (ctDNA) in untreated patients (pts) with cancer: Implications for early cancer detection (ECD)
Presenter: Yoshiaki Nakamura
Session: Poster session 14
1225P - Combining ctDNA and tissue-based-genomic profiling in advanced cancer: A real-world evidence prospective study in non-Western patients treated at Gustave Roussy cancer campus
Presenter: Tony Ibrahim
Session: Poster session 14
1226P - Multi-site validation of a deep learning solution for HER2 profiling of breast cancer from H&E-stained pathology slides
Presenter: Salim Arslan
Session: Poster session 14
1227P - Novel in vivo photonics-immunoassay system, inPROBE, for the rapid detection of HER2 in breast cancer
Presenter: Magdalena Staniszewska
Session: Poster session 14
1228P - A circulating tumor cell (CTC) based assay for diagnostic immunocytochemistry profiling of lung cancer
Presenter: Nitesh Rohatgi
Session: Poster session 14